Keyphrases
Aging
9%
Alzheimer Disease Research Center
9%
Alzheimer's Disease
18%
Alzheimer's Disease Biomarkers
100%
Amyloid PET
9%
Biomarker Testing
100%
Clinical Assessment
100%
Clinical Covariates
9%
Clinical Dementia Rating
36%
Clinical Measures
9%
Cognitive Composite Scores
18%
Cognitive Decline
9%
Cognitive Functioning
9%
Cognitive Impairment
9%
Cognitively Normal
100%
Community-based Cohort
9%
Competing Risks
9%
CSF Biomarkers
9%
Cumulative Incidence Function
9%
Demographic Covariates
9%
Determining Functionals
9%
Disease Understanding
9%
Driving Cessation
100%
Early Planning
9%
Female Sex
9%
Full Model
9%
Functional Mobility
9%
Functional Outcome
9%
Hazard Ratio
18%
High Risk
9%
Increased Incidence
9%
Knight
9%
Longitudinal Observation Study
9%
Model Progression
9%
Neurological Examination
9%
Neuropsychological Assessment
9%
Neuropsychological Tests
9%
Normal Aging
9%
Old Age
9%
Older Adults
9%
Older Drivers
100%
PET Imaging
9%
Phosphorylated tau
18%
Poor Performance
9%
Population-based Incidence
9%
Promoting Independence
9%
Prospective Longitudinal Study
9%
Risk Factors
9%
Sporadic Alzheimer's Disease
27%
Subdistribution Hazard
9%
Total tau
18%
US Population
9%
Medicine and Dentistry
Alzheimer's Disease
100%
Alzheimer's Disease Biomarkers
100%
Amyloid Protein
25%
Biological Marker
75%
Cerebrospinal Fluid
50%
Clinical Assessment
100%
Clinical Dementia Rating
100%
Clinician
25%
Cognitive Defect
25%
Cumulative Incidence
25%
Hazard Ratio
50%
Positron Emission Tomography
50%
Tau
100%
Neuroscience
Alzheimer's Disease
100%
Amyloid Protein
16%
Clinical Assessment
100%
Clinical Dementia Rating
66%
Cognitive Disorders
16%
Neuropsychological Assessment
16%
Positron Emission Tomography
33%
Psychology
Alzheimer's Disease
100%
Cerebrospinal Fluid
33%
Cognitive Decline
16%
Cognitive Functioning
16%
Cognitive Impairment
16%
Composite Score
33%
Hazard Ratio
33%
Neuropsychological Assessment
16%
Biochemistry, Genetics and Molecular Biology
Amyloid Protein
25%
Positron Emission Tomography
50%
Tau
100%